Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Regulus Therapeutics Inc. (RGLS) Report Updated: Nov 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

Regulus Therapeutics Inc. (RGLS)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: AVXL, EGRX, ZIOP, NBIX

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: D down downgrade
Last Week: C same upgrade
Two Weeks Ago: D up no change
service keys

Regulus Therapeutics Inc.© quotemedia

Company Profile

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Recent News: Regulus Therapeutics Inc.